How does lipid management influence CABG outcomes?

• A. Statins have no effect
• B. Statin therapy improves graft patency and reduces adverse events
• C. Lipids do not influence post-CABG outcomes
• D. LDL lowering worsens graft patency

Answer: (B)

Managing lipids around CABG matters because graft failure is driven by ongoing atherosclerosis, plaque instability, and inflammation in both the grafts and the native vessels. Statin therapy helps on multiple fronts: it lowers LDL, which slows atherosclerotic progression; it stabilizes plaques; it improves endothelial function; and it has anti-inflammatory and anti-proliferative effects that reduce neointimal hyperplasia in bypass grafts. These combined actions lead to better patency of grafts (both vein and arterial conduits) and fewer adverse cardiovascular events such as myocardial infarction, stroke, or death after CABG.

Thus, lipid management with statins is associated with improved graft patency and reduced adverse events. Statements claiming no effect, that LDL lowering worsens patency, or that lipids don’t influence post-CABG outcomes contradict the clinical and physiological benefits of lipid optimization in this setting.